Gardasil® needs a new consent form

Expert Review of Vaccines

Volumn 8, Issue 12, 2009, Pages 1613-1614

  Harper, Diane M ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE; WART VIRUS VACCINE; HUMAN PAPILLOMAVIRUS VACCINE L1, TYPE 6,11,16,18;

ANAPHYLAXIS; AUTOIMMUNE DISEASE; CANCER DIAGNOSIS; CANCER IMMUNIZATION; CANCER RISK; CANCER SCREENING; COLPOSCOPY; DRUG FATALITY; EDITORIAL; GUILLAIN BARRE SYNDROME; HEALTH PROGRAM; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; INFORMED CONSENT; LOW BIRTH WEIGHT; MENINGITIS; MOTOR NEURON DISEASE; MYELITIS; PANCREATITIS; PAPANICOLAOU TEST; PREMATURITY; PRIMARY PREVENTION; PRIORITY JOURNAL; TUMOR BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VENOUS THROMBOEMBOLISM; ALPHAPAPILLOMAVIRUS; FEMALE; PAPILLOMAVIRUS INFECTION; UTERINE CERVIX TUMOR; VAGINA SMEAR;

ALPHAPAPILLOMAVIRUS; CONSENT FORMS; FEMALE; HUMANS; INFORMED CONSENT; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 73849108866     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.09.120     Document Type: Editorial

References (10)

1. Slade BA, Leidel L, Vellozzi C et al. Postlicensure safety surveillance for qHPV recombinant vaccine. JAMA 302(7), 750-757 (2009).
2. US Department of Health and Human Services. Healthy People 2010 (2nd Edition). With Understanding and Improving Health and Objectives for Improving Health (Part A. Focus Area 3. Cancer). US Government Printing Office, Washington, DC, USA (2000).
3. Sawaya GF, Grimes DA. New technologies in cervical cytology screening: a word of caution. Obstet. Gynecol. 94(2), 307-310 (1999).
4. Prendiville W. The treatment of CIN: what are the risks? Cytopathology 20(3), 145-153 (2009).
5. Brown DR, Kjaer SK, Sigurdsson K et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J. Infect. Dis. 199, 926-935 (2009).
6. Olsson S-O, Paavonen J. Impact of HPV 6/11/16/18 vaccine on abnormal Pap tests and procedures. Presented at: 25th International Papillomavirus Conference. Malmo, Sweden, 8-12 May 2009 (Abstract O-01.08).
7. Barnabas RV, Laukkanen P, Koskela P, Kontula O, Lehtinen M, Garnett GP. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med. 3, e138 (2006).
8. Castle PE, Solomon D, Saslow D, Schiffman M. Predicting the effect of successful human papillomavirus vaccination on existing cervical cancer prevention programs in the United States. Cancer 113(10 Suppl.), 3031-3035 (2008).
9. Day PM, Thompson CD, Buck CB, Pang YYS, Lowy DR, Schiller JT. Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition. J. Virol. 81(16), 8784-8792 (2007).
10. Amyotrophic Lateral Sclerosis Fact Sheet www.ninds.nih.gov/disorders/ amyotrophiclateralsclerosis/detail- amyotrophiclateralsclerosis.htm (Accessed 30 August 2009)